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Abstract 
Chromosomal Microarray Analysis (CMA) is currently considered to be the first-tier 
clinical test for neurodevelopmental disorders, such as Intellectual Disability (ID)/ 
Developmental Delay (DD) and Autism Spectrum Disease (ASD) due to its ability to 
detect Copy Number Variants (CNVs). CNVs are defined as segments of DNA which 
might either be deleted or duplicated and represent the most prevalent type of 
structural variation in the human genome. Recently, they have been found to be the 
causative agent for approximately 15-20% of previously undiagnosed cases of neuro 
developmental disorders. The unceasingly growing number of microdeletion and 
microduplication syndromes (MMSs), identified through CMA, has significantly 
altered the diagnostic approach to disorders such as ID and ASD.  
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CNV: Copy Number Variant 
 
ID: Intellectual Disability 
 
DD: Developmental Delay 
 
ASD: Autism Spectrum Disorder 
 
ADHD: Attention Deficit Hyperactivity Disorder 
 
VUS: Variant of Unknown Significance 
 
MMS: Microdeletion and Microduplication Syndromes 
 
FISH: Fluorescent in situ Hybridization 
 
BAC: Bacterial Artificial Chromosome 
 
UPD: Uniparental Disomy 
 
ACMG: American College of Medical Genetics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aristotle Biomedical Journal, Vol 2 No 2 e-ISSN: 2653-9748 
3 
 
Introduction 
The implementation of array 
Comparative Genome Hybridization 
(aCGH) and array of Single-
Nucleotide Polymorphism (SNP) into 
the genome-wide detection of Copy 
Number Variants (CNVs) related to 
Intellectual Disability (ID) has 
revolutionized the field and has 
significantly broaden the diagnostic 
spectrum. 
Chromosomal Microarray Analysis 
(CMA) is currently considered to be 
the first-line diagnostic test for 
Neurodevelopmental disorders, such as 
Intellectual Disability (ID)/ 
developmental delay (DD), autism 
spectrum disorder (ASD) and attention 
deficit hyperactivity disorder (ADHD) 
with a diagnostic yield of 
approximately 15-20% (Miller et al., 
2010). Intellectual Disability is defined 
as the restricted intellectual and 
behavioral functioning of an individual 
which originates before the age of 18 
years/ during the developmental period 
and can be further categorized into one 
of the following: mild, moderate, 
severe or profound (Birch et al., 1970; 
Lee et al., 2019). Nowadays, the 
classification criteria are based more 
on the adaptive functioning of the 
individual rather than his IQ (Bass and 
Skuse, 2018). ID occurs in 1-3 % of 
the general population but is found to 
have a higher prevalence among 
individuals with concurrent congenital 
deficits. In the majority of cases, 
especially when referring to a non-
syndromic ID, the underlying cause 
cannot be defined. Copy number 
variants (CNVs), including 
microdeletions and microduplications, 
have recently been found to be highly 
implicated in the aetiology of ID and 
count for approximately 15-20 % of 
patients with previously 
unrecognized/undiagnosed 
neurodevelopmental disorders 
(Cooper, 2011). They can be inherited 
or arise de novo and they range in size 
from 15 kb to 1 Mb in length. 
Furthermore, they can be classified as 
pathogenic, benign or variants of 
unknown significance (VUS) based on 
various criteria (Table 2). 
The detection of numerical and 
balanced or unbalanced structural 
chromosomal abnormalities was 
traditionally achieved through the 
cytogenetic analysis of G-banded 
karyotype. This technique successfully 
contributed to the diagnosis of various 
genetic syndromes. However, due to its 
lack of sensitivity and a minimum 
resolution of 5-10 Mb, arose the need 
for a technique with an improved 
diagnostic resolution (Vickers and 
Gibson, 2018). The evolution of 
Fluorescent in situ hybridization 
(FISH) has managed to accomplish a 
minimum resolution of 40-250 kb and 
has significantly ameliorated the 
detection of submicroscopic 
chromosomal imbalances and 
rearrangements. This particular method 
uses sequence complementarity in 
order for fluorescently labeled DNA 
probes to be hybridized to specific 
genes of interest in interphase cells or 
metaphase chromosomes. Its 
application resulted in the 
identification of more than 500 
syndromes which are currently well 
characterized. However, its greatest 
limitation is the need for prior 
knowledge of the chromosomal 
region(s) of interest and therefore can 
be strictly implemented in the 
detection of one or a few certain 
candidate chromosomal loci and 
cannot be utilized for genome-wide 
analysis (Shaffer, 2005; Beaudet, 
2013). On the contrary, the application 
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of CMA is not only able to detect 
genome-wide submicroscopic 
deletions and duplications at the same 
time and in a single assay, but also 
achieves it with even higher resolution 
compared to G-banded karyotype and 
FISH analysis (Miller et al, 2010; 
Beaudet, 2013) .CMA has increased 
the diagnostic yield up to 10%, 
especially for individuals with 
previously undetermined/unexplained 
developmental disabilities. 
Chromosomal Microarray Analysis 
Technique 
Microarray-based genomic copy-
numbers analysis, commonly known as 
chromosomal microarray analysis or 
molecular karyotype, encompasses all 
types of area-based genomic analyses. 
Two types of CMA that are currently 
mostly utilized are array-based 
comparative genomic hybridization 
(aCGH) and single nucleotide 
polymorphism (SNP) arrays:  
1) The aCGH technique is able to 
detect CNVs using bacterial artificial 
chromosome (BAC) or oligonucleotide 
probes that are approximately 60-70bp 
long. By this method, patient DNA and 
control DNA samples are fluorescently 
labelled with different colors and are 
united on microarrays, where 
hybridization takes place. Any 
variations in fluorescence intensities 
reveal gains or losses of genomic 
segments, and therefore may allow the 
identification of CNVs which account 
for the particular deletion or 
duplication (Theisen, 2008). The 
application of aCGH has permitted an 
etiologic diagnosis in 15-20% of 
individuals with previously 
undetermined/unexplained 
developmental delay/intellectual 
disability (D’Arrigo et al, 2016). 
2) The SNP array technique is based 
on the usage of two oligonucleotide 
probes that are approximately 25bp 
long and target even the slightest 
variations throughout the genome. 
Regarding to SNP arrays, only the 
patient’s DNA is labelled and 
hybridized to the array. The signal 
intensity of the patient’s sample is then 
compared to allele-specific probes, 
which correlate to approximately 1,500 
SNPs and correspond to a specific 
genetic location (Ji et al, 
2004).Compared to aCGH, microarray-
based SNP analysis is able to spot 
cases of uniparental disomy (UPD) 
which is defined as the inheritance of 
two copies of a chromosome from the 
same parent, instead of inheriting a 
maternal and a paternal copy. 
Furthermore, SNP analysis enables the 
detection of low-level mosaicism (as 
low as 5%), a condition in which an 
individual consists of 2 or more 
genetically different sets of cells (Flore 
and Milunsky, 2012; Miller et al, 
2010) (Table 1). Even though both 
array-based technologies are unable to 
identify balanced translocations such 
as Robertsonian or other reciprocal 
translocations, balanced inversions or 
insertions, a respectable amount of 
cytogenetic events that are ostensibly 
balanced, turn out to have a 
submicroscopic imbalance when 
analyzed with high resolution array 
technology (Feenstra et al, 2011; De 
Gregori et al, 2007). 
Apart from distinct microdeletions or 
microduplications, copy number 
variants (CNVs) represent a different 
entity which have proven to be 
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pathogenic in many previously 
undiagnosed disorders. The above-
mentioned techniques have contributed 
to their detection in different extent. 
SNP arrays seem to prevail in such  
 
diagnoses, due to their higher probe 
density and coverage (Li and Olivier, 
2013). 
 
 
Table 1: CMA techniques comparison
aCGH                       SNP array 
-oligonucleotideprobelength: 60-70bp -oligonucleotideprobelength: ~25bp 
-patient DNA + control DNA samples -hybridization of patient DNA only 
-fluorescentlylabelled -fluorescentlylabelled 
-diagnosis based on fluorescence 
intensities’ differences  
-diagnosis based on comparison of patient’s 
sample DNA to allele-specific probes 
-no detection of UPD and mosaicism -detection of UPD and mosaicism 
 
Copy Number Variants (CNVs) 
Copy number variants (CNVs) are 
defined as a type of structural 
alteration concerning the number of 
copies of specific regions of DNA, 
which can either be deleted or 
duplicated. They vastly contribute to 
the genetic variation found among 
individuals and can be inherited or 
arise de novo. CNVs have multiple 
functional effects; they usually 
encompass genes that are dosage 
sensitive such as the ones involved in 
the brain development. In fact, recent 
studies have demonstrated their major 
implication in the aetiology of certain 
neurodevelopmental disorders 
including, but not limited to, ID, DD, 
ASD and ADHD. Additionally, they 
can affect gene expression at a distance 
or insert into varying positions of the 
genome. They can be characterized by 
incomplete penetrance and variable 
expressivity, furtherly complicating the 
interpretation of their contribution to 
certain diseases. Multiple CNVs are 
considered to be risk factors for 
various diseases such as schizophrenia. 
The American College of Medical 
Genetics and Genomics (ACMG) 
recently published the clinical 
classification and description of CNVs 
(Table 2) which is based on their size, 
genomic content, existing databases 
and parental analysis. According to the 
current ACMG clinical classification, 
CNVs can be pathogenic, likely 
pathogenic, Variants of unknown 
significance (VUS), likely benign and 
benign (Kearney, 2011).  
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Table 2: ACMG classification guidelines 
              CNV classification Description 
Pathogenic Clinically significant in multiple peer-
reviewed publications/overlapping CNV of 
known genomic syndrome. 
Overlapping CNV of patients reported in 
database (es. DECIPHER,DGV,ClinGen). 
Likely Pathogenic Described in a single case report with 
similar phenotype to the patient. 
Contains a gene relevant and specific to the 
reason for patient referral. 
 
Variant of unknown significance (VUS) Reported in contradictory publications 
and/or databases. 
Contains genes that are not known to be 
dosage sensitive. 
Likely Benign Large CNV that is gene poor/absence of 
regulatory elements.  
Not reported in databases as benign. 
Benign Common polymorphism/known benign 
variant in multiple peer-reviewed 
publications. 
 
Ideally, parental analysis through 
FISH, CMA or qPCR should be 
performed in order to interpretate the 
pathogenicity of the identified CNVs. 
The presence of a CNV in an affected 
parent indicates its pathogenicity. 
However, the inheritance of a CNV by 
a phenotypically unaffected parent 
does not exclude its contribution to the 
disease; incomplete penetrance or 
variable expressivity may be the 
underlying causes of this phenomenon 
(Miller, 2010). 
In a similar way, even though a CNV 
occurring de novo has a greater chance 
of being pathogenic compared to an 
inherited one, further investigation of 
the variant’s correlation to the 
particular phenotype is necessary, 
before classifying it as pathogenic. The 
clinical interpretation of VUS poses a 
significant diagnostic dilemma for 
clinicians and geneticists. According to 
some, such a finding should not be 
made known to the patient; if the 
particular variant is not responsible for 
the condition, it will only cause 
unnecessary frustration. On the other 
hand, it may be the causative agent in 
regard to the disease and omitting such 
valuable information might severely 
affect the future decision-making 
process (Hoffman-Andrews, 2017). 
The ACMG suggests that a VUS 
should not be utilized in the clinical 
determination; however, there should 
be a continuous attempt to resolve the 
classification of the variant to 
“pathogenic” or “benign” (Kearney, 
2011). In the meantime, additional 
monitoring of the patient for the 
disorder in question must be 
considered by clinicians. Finally, 
genetic laboratories ought to be alert 
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for any possible changes in the 
literature/in databases concerning the 
transformation of VUS to likely 
pathogenic or likely benign. 
 
Microdeletion and microduplication 
syndromes 
The greatest contribution of CMA lies 
in the diagnosis and research of 
various genetic disorders that are 
caused by infrequent genomic 
rearrangements and could not until 
recently be discovered. The 
unceasingly growing number of 
microdeletion and microduplication 
syndromes (MMSs), identified through 
this method, has significantly altered 
the diagnostic approach to 
neurodevelopmental disorders such as 
ID and ASD (Weise et al., 2011; 
Nevado et al., 2014;). MMSs are 
caused by microscopic and 
submicroscopic gains or deletions of 
various genomic regions and 
frequently appear with a recognizable 
collection of clinical features. Certain 
gene segments can be both deleted and 
duplicated, a phenomenon known as a 
reciprocal duplication. It usually 
appears with similar but less severe 
clinical effects, compared to the ones 
deriving from the deletion (Watson et 
al., 2014; Conrad et al., 2010; Kiezun 
et al., 2013).Some of the best described 
microdeletion and reciprocal 
microduplication syndromes that are 
caused by CNVs and have been 
identified through CMA are presented 
below (Table 3).  
1. 7q11.23 distal microdeletion 
syndrome 
It is referred to the distal deletion of 
the Williams-Beuren region. Epilepsy 
and neurodevelopmental disorders 
commonly appear.  
2. 7q11.23 microduplication 
syndrome 
Speech disorders, ID, ASD, epilepsy 
and distinctive craniofacial features 
such as bracycephaly, broad nasal tip 
and straight eyebrows have been 
observed in patients. 
3. 15q24 microdeletion 
syndrome/microduplication 
syndrome 
Similar clinical features with varying 
severity are observed in both 
syndromes and include: failure to 
thrive, ID, distinctive facial 
characteristics (es. Long face, anterior 
hairline, hyperteleorism and long 
philtrum). Hypotonia, behavioral 
abnormalities, hearing impairment and 
hernias have also been reported in 
various patients. 
4. 16p11.2 microdeletion syndrome 
Mild ID, autism, epilepsy, 
macrocephaly (apparent by 2 years of 
age), microphthalmia and obesity are 
frequently associated with this 
syndrome.  
5. 16p11.2 microduplication 
syndrome 
The reciprocal duplication usually 
appears with microcephaly, ID, ASD 
and schizophrenia. 
6. 17p11.2 microdeletion ( Smith-
Magenis ) syndrome 
Neurodevelopmental and psychiatric 
disorders, sleep disturbance, 
craniofacial and skeletal anomalies are 
the most frequently observed findings 
in SMS.  
7. 17p11.2 microduplication 
(Potocki-Lupski) syndrome 
The reciprocal duplication presents 
similar findings including: hypotonia, 
poor feeding, growth delay, learning 
disabilities, mild to moderate ID, ASD 
and ADHD. Structural cardiovascular 
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anomalies (es dilated aortic root) and 
sleep disturbance (obstructive and 
central sleep apnea) are commonly 
reported in patients. 
8. 17q21.31 microdeletion (Koolen-
De Vries) syndrome 
This condition is characterized by 
hypotonia, mild to moderate ID, 
epilepsy, macrocephaly, dysmorphic 
facial alterations, congenital heart 
anomalies (es dilation of the aortic 
root) and congenital renal/urologic 
anomalies.  
9. 17q21.32 microduplication 
syndrome 
Hypotonia, ASD and developmental 
disorders have been associated with 
this newly described condition.  
(Goldenberg, 2018; Nevado, 2014; 
Weise, 2012; Watson, 2014).  
 
 
 
 
Table 3: Microdeletion/ Microduplication Syndromes 
1. 7q11.23 distal deletion / 7q11.23 duplication syndrome 
2. 15q24 deletion / 15q24 duplication syndrome 
3. 16p11.2 deletion / 16p11.2 duplication syndrome 
4. 17p11.2 deletion (Smith Magenis) / 17p11.2 duplication (Potocki-Lupski) 
syndrome 
5. 17q21.31 deletion (Koolen-De Vries) / 17q21.31 duplication syndrome 
 
Conclusions 
The clinical implementation of CMA 
in the discovery of ID-related CNVs 
has notably raised the number of 
recognizable MMSs and has 
revolutionized the diagnostic approach 
to intellectual disability. When applied 
as a first-tier clinical test for broadly 
defined neurodevelopmental disorders, 
CMA can detect pathogenic variants, 
including CNVs that were undetectable 
by other techniques such as 
karyotyping and FISH, in 
approximately 15% of individuals. 
However, specific clinical genetic 
training and cautiousness in regard to 
the interpretation of certain findings  
such as VUS, is needed, as well as 
additional counseling skills for the 
communication of the results to 
patients. Nowadays with all the  
 
advances in technology, the continuous 
sharing of information across 
laboratories and clinicians is necessary 
so that uniformal interpretation of 
results can be achieved. Thus, the 
establishment of better diagnostic 
definitions may hopefully lead to the 
provision of personalized medical 
treatment in the near future. 
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